201 384

Cited 0 times in

Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.

Authors
Rhee, Y; Kang, M; Min, Y; Byun, D; Chung, Y; Ahn, C; Baek, K; Mok, J; Kim, D; Kim, H; Kim, Y; Myoung, S; Lim, SK
Citation
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 17(12):1801-1807, 2006
Journal Title
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
ISSN
0937-941X1433-2965
Abstract
INTRODUCTION: A randomized, double-blind, prospective, 24-week clinical trial was performed to evaluate the effects of a combinative agent, Maxmarvil, of calcitriol (0.5 mug) and alendronate (5 mg) on bone metabolism in postmenopausal women.



METHODS: A total of 217 postmenopausal women with osteoporosis were enrolled; 199 patients were randomly assigned to one of two treatment groups (Maxmarvil group or alfacalcidol group). None of the patients were vitamin-D-deficient, as assessed by serum 25-hydroxyvitamin D (25(OH)D), nor had they received any drugs affecting bone metabolism before enrollment. Bone mineral densities (BMD) of L1-L4 and the femur were measured by dual-energy X-ray absorptiometry (DXA) at the initial assessment and after 6 months of treatment. Serum biochemical assays, including serum calcium, 24-h urinary calcium excretion, and bone turnover markers (both bone-specific alkaline phosphatase [bsALP] and urine N-telopeptide [NTx]), were performed at the baseline and after 3 and 6 months of treatment.



RESULTS: In the Maxmarvil group, the BMD of the lumbar spine increased up to 2.42+/-0.5% from the baseline after 6 months (p<0.05). On the other hand, the change in BMD in the alfacalcidol group was 0.28+/-0.5% after 6 months. There was no significant difference in femoral BMD between the two groups. The levels of bsALP and NTx were significantly lower in the Maxmarvil group than in the alfacalcidol group (-22.04+/-3.9% vs. -11.42+/-2.8% [p<0.05] and -25.46+/-5.2% vs. 1.24+/-6.2% [p<0.001], respectively). Interestingly, there was a significantly smaller amount of 24-h urinary calcium in the Maxmarvil group (p<0.05).



CONCLUSIONS: Our study demonstrates that a combination of calcitriol and alendronate is quite effective in preventing bone loss, with the advantage of lesser hypercalciuric effect of calcitriol in the postmenopausal osteoporotic women.
MeSH terms
Alendronate/adverse effectsAlendronate/therapeutic use*Alkaline Phosphatase/bloodBiological Markers/analysisBone Density/physiologyBone Density Conservation Agents/adverse effectsBone Density Conservation Agents/therapeutic use*Calcitriol/adverse effectsCalcitriol/therapeutic use*Collagen Type I/urineDouble-Blind MethodDrug CombinationsFemaleFemur/metabolismHumansHydroxycholecalciferols/adverse effectsHydroxycholecalciferols/therapeutic useKorea/epidemiologyLumbar Vertebrae/metabolismMiddle AgedOsteoporosis, Postmenopausal/drug therapy*Osteoporosis, Postmenopausal/epidemiologyOsteoporosis, Postmenopausal/metabolismPeptides/urineTreatment Outcome
DOI
10.1007/s00198-006-0200-4
PMID
17019520
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Endocrinology & Metabolism
AJOU Authors
정, 윤석김, 대중
Files in This Item:
Full-Text Not Available.txtDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse